Providence Medical Technology, Inc.
$5.6M 2,215 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. reported $5,640,126.55 across General Payments, Research, and Ownership to 988 physicians and teaching hospitals across 1,518 transactions.
- $5.6M Top quartile payer
- All-tracks total
- 1,518 Top quartile volume
- Transactions
- 988 Above-median reach
- Recipients
- −$310.6K
- General Payments vs PY2023
Marinus Pharmaceuticals, Inc. reported $5,640,126.55 across all CMS Open Payments tracks (General + Research + Ownership) to 988 physicians and teaching hospitals in Program Year 2024 - ranking #258 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $279,218.12, averaging $5.7K per recipient.
How Marinus Pharmaceuticals, Inc.'s $5.6M all-tracks total breaks down
Marinus Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
38/100
Total payments
D
62/100
Transaction volume
F
21/100
Physician reach
F
17/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer marinus-pharmaceuticals-inc Marinus Pharmaceuticals, Inc.
$5.6M · #258/1,925 · 0.0% industry · PY2024
- TOT $5.6M
- RANK #258
- SHARE 0.0%
- TXN 1,518
- RCP 988
- CAT 4
- GEN $279.2K
- ΔGEN −$310.6K
- TOP1 22.7%
- PY 2024
Volume peers
Nearest volume peer: Providence Medical Technology, Inc. ($5.6M)
Marinus Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Marinus Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $310.6K (−52.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: IMMEDICA PHARMA US, INC.PY2023: IMMEDICA PHARMA US, INC.PY2024: Marinus Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $589,841.00
- PY2024
- $279,218.12
What the Data Shows for Marinus Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Marinus Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
55 transactions worth $142.5K make "Compensation for Services Other Than Consulting" the top general-payment category in the 4-category breakdown below, 51.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Marinus Pharmaceuticals, Inc. made 4 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $142.5K, 51.0% of General Payments.
Marinus Pharmaceuticals, Inc. reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (51.0%), Consulting Fee (28.6%), and Food and Beverage (10.9%). The remaining 1 category make up 9.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Marinus Pharmaceuticals, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $142.5K | 55 | 51.0% |
| Consulting Fee | $79.8K | 20 | 28.6% |
| Food and Beverage | $30.4K | 864 | 10.9% |
| Travel and Lodging | $26.5K | 49 | 9.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $139,303.75 (49.9%) of $279,218.12 in this company's General Payments records across 557 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Marinus Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Sarah Noonberg
$63,396.25 across 11 reported transactions
- 2
Michael Rogawski
$27,980.00 across 1 reported transactions
- 3
Alison Marie Dolce
$18,478.87 across 20 reported transactions
- 4
Rajsekar Rajaraman
$15,662.41 across 14 reported transactions
- 5
Jesus Pina Garza
$13,786.22 across 28 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Marinus Pharmaceuticals, Inc. ranks #258 of 1,925 by total payments (top 13% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,116 of 1,838 by HHI (bottom 39% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- BioHorizons Implant Systems Inc. : $1.4M total payments, HHI 813
- PTC Therapeutics, Inc. : $464.2K total payments, HHI 811
- Planmeca USA, Inc. : $214.2K total payments, HHI 810
- Elevation Spine, Inc. : $38.6K total payments, HHI 810
- Terumo Cardiovascular Systems Corporation : $22.7K total payments, HHI 809
- Pierre Fabre Pharmaceuticals, Inc. : $53.6K total payments, HHI 809
- Marinus Pharmaceuticals, Inc. (this company) : $279.2K total payments, HHI 807
- 3B Medical, Inc. : $29.3K total payments, HHI 805
- ModernaTX, Inc. : $2.4M total payments, HHI 803
- Community Blood Center : $72.5K total payments, HHI 797
- Acrotech Biopharma Inc. : $317.9K total payments, HHI 793
- KaVo Dental Technologies LLC : $990.42 total payments, HHI 792
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Marinus Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Marinus Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Marinus Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Karyopharm Therapeutics Inc.
$5.6M 5,247 recipients
Compare payment profiles
DeRoyal Industries, Inc.
$5.6M 82 recipients
Compare payment profiles
Ascendis Pharma Inc
$5.7M 2,549 recipients
Compare payment profiles
Nalu Medical, Inc.
$5.7M 9,707 recipients
Compare payment profiles
Highridge Medical LLC
$5.8M 2,278 recipients
Compare payment profiles
Put this to use
Marinus Pharmaceuticals, Inc. ranks #258 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Marinus Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Marinus Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.